Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Pictet Asset Management Holding SA raised its stake in BioNTech (BNTX) by 41.6%, buying 26,119 shares to hold 88,838 shares valued at $8,457,000 at quarter-end.
• COO Sierk Poetting sold 50,000 shares under a pre‑arranged Rule 10b5‑1 plan for an average $110.56/share (≈$5,528,000), reducing his ownership by 11.13%.
• Analysts have a consensus rating of “Moderate Buy” with a $133.13 target, while BNTX trades around $97.54 and recently reported a quarterly EPS of -$0.39 and negative net margins, indicating mixed fundamentals despite analyst optimism.

Pictet Asset Management Holding SA lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,838 shares of the company's stock after acquiring an additional 26,119 shares during the quarter. Pictet Asset Management Holding SA's holdings in BioNTech were worth $8,457,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in BNTX. Financial Consulate Inc. bought a new stake in shares of BioNTech in the third quarter worth approximately $36,000. Huntington National Bank grew its position in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company's stock valued at $40,000 after buying an additional 380 shares during the period. Tower Research Capital LLC TRC grew its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after buying an additional 305 shares during the period. Rakuten Securities Inc. grew its position in BioNTech by 188.1% during the third quarter. Rakuten Securities Inc. now owns 1,043 shares of the company's stock valued at $103,000 after buying an additional 681 shares during the period. Finally, Hantz Financial Services Inc. grew its position in BioNTech by 100.3% during the third quarter. Hantz Financial Services Inc. now owns 1,146 shares of the company's stock valued at $113,000 after buying an additional 574 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent research reports. Truist Financial upgraded shares of BioNTech to a "strong-buy" rating in a research report on Wednesday, March 25th. BMO Capital Markets cut their target price on shares of BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 11th. Leerink Partners lowered shares of BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 target price for the company. in a research report on Monday, February 2nd. The Goldman Sachs Group restated a "buy" rating on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group restated a "buy" rating on shares of BioNTech in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus target price of $133.13.

Insider Buying and Selling at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

BioNTech Stock Performance

BNTX opened at $97.54 on Friday. The firm has a market cap of $24.67 billion, a P/E ratio of -18.61 and a beta of 1.36. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a 50 day simple moving average of $97.52 and a two-hundred day simple moving average of $101.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. Equities analysts forecast that BioNTech SE Sponsored ADR will post -4.55 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.